Navigation Links
Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer
Date:3/25/2008

YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, March 25 /PRNewswire-FirstCall/ -- Galil Medical, a global cryotherapy company, today announced that Martin J. Emerson has been appointed President and Chief Executive Officer. Galil Medical is a market leader in cryotherapy technology for the minimally invasive treatment of cancerous and non-cancerous tumours. Mr. Emerson is an experienced and successful medical device industry executive, and was most recently President and CEO of American Medical Systems (AMS). He will be replacing Chen Barir, who will continue to serve on the Galil Medical Board of Directors.

Chen Barir commented, "Galil Medical is very pleased to have been able to attract an executive with the leadership experience and stature of Marty Emerson. We are confident that Marty will be able to help Galil Medical sustain the growth that has been recorded since our December 2006 reorganisation and recapitalisation financing."

"I am very excited to be joining Galil Medical," said Mr. Emerson. "The company has developed innovative cryotherapy solutions to treat prostate cancer and renal tumours and has a promising product pipeline for the Women's Health and Interventional Radiology markets. I look forward to working with the talented team to expand the opportunities for Galil Medical's industry leading technology around the globe."

Mr. Emerson has a strong track record of over 20 years of accomplishments in the medical device industry, most recently as President and Chief Executive Officer of AMS. During his tenure at AMS, he held executive roles including Vice President and General Manager of International, Executive Vice President of Global Sales and Marketing and Chief Operating Officer. Prior to joining AMS, he held senior roles in the overseas operations for several American-based companies including Baxter International and Boston Scientific.

About Galil Medical

Galil Medical develops, manufactures and markets innovative products utilising a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical systems enable minimally invasive, targeted ablation of benign and cancerous tumours while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumours while protecting adjacent structures.

Galil Medical is a global medical device company with offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London, shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (NASDAQ: ELRN) and RDC Rafael Development Corporation, Ltd. For more information, please visit http://www.galilmedical.com

Pam Schwartz

Communications Manager

Galil Medical

T: +972-4-909-3273

M: +972-52-625-4443

F: +972-4-959-1077

pam.schwartz@galilmedical.com


'/>"/>
SOURCE Galil Medical
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical to present at BioCentury Conference
2. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
3. Medical Research Award Goes to Adult Stem Cell Scientists at a Kansas Not-for-Profit Organization
4. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
5. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
6. BioMS Medical Announces 2007 Year End Results
7. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
8. GHI Medical Deploys New Test to Help Determine Hair Loss
9. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):